Evidence map›Paper›PMID 33210178›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2021

The efficacy of in vivo administration of Apremilast on mesenchymal stem cells derived from psoriatic patients.

Anna Campanati, Miriam Caffarini, Federico Diotallevi, Giulia Radi, Guendalina Lucarini, Mariangela Di Vincenzo, Monia Orciani, Annamaria Offidani

Abstract readControlled Clinical Trial
PubMed Publisher
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Mesenchymal Stem Cells and Psoriasis: Systematic Review.International journal of molecular sciences · 2022
    Pooled it
  3. Effects of Adalimumab on Mitochondria of Psoriatic Mesenchymal Stem Cells.Journal of cellular and molecular medicine · 2025
    Article
  4. Review
  5. Review
  6. Review
  7. Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.International journal of molecular sciences · 2023
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Anna CampanatiDepartment of Clinical and Molecular Sciences, Dermatology Clinic, Università Politecnica delle Marche, Ancona, Italy.ORCID http://orcid.org/0000-0002-3740-0839
Miriam CaffariniDepartment of Clinical and Molecular Sciences, Histology, Università Politecnica delle Marche, Via Tronto 10/A, 60126, Ancona, Italy.
Federico DiotalleviDepartment of Clinical and Molecular Sciences, Dermatology Clinic, Università Politecnica delle Marche, Ancona, Italy.
Giulia RadiDepartment of Clinical and Molecular Sciences, Dermatology Clinic, Università Politecnica delle Marche, Ancona, Italy.
Guendalina LucariniDepartment of Clinical and Molecular Sciences, Histology, Università Politecnica delle Marche, Via Tronto 10/A, 60126, Ancona, Italy.
Mariangela Di VincenzoDepartment of Clinical and Molecular Sciences, Histology, Università Politecnica delle Marche, Via Tronto 10/A, 60126, Ancona, Italy.
Monia OrcianiDepartment of Clinical and Molecular Sciences, Histology, Università Politecnica delle Marche, Via Tronto 10/A, 60126, Ancona, Italy. m.orciani@univpm.it.
Annamaria OffidaniDepartment of Clinical and Molecular Sciences, Dermatology Clinic, Università Politecnica delle Marche, Ancona, Italy.
Marche Polytechnic University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPsoriasis cellular hallmarks, such as the imbalance between Th1/Th17 and Th2 cytokines and the dysregulated expression of vascular endothelial growth factor (VEGF), inducible nitric oxide synthase, (iNOS) and indoleamine 2,3-dioxygenase (IDO), are all detectable in mesenchymal stem cells (MSCs) suggesting that psoriasis originates at mesenchymal level. AIM OF THE STUDY: In this scenario, MSCs may become the new therapeutic target and interest in the effects of traditionally used drugs, such as Apremilast, on MSCs has greatly increased. MATERIALS AND

methodsMSCs from control subjects (C-MSCs) and from psoriatic patients before (PsO MSCs T0) and after in vivo treatment with Apremilast (PsO-MSCs T12) were isolated and characterized; subsequently, the effects of Apremilast on VEGF, iNOS and IDO expression were evaluated by immunocytochemistry (ICC). The expression of VEGF, iNOS and IDO was also detected in skin sections by immunohistochemistry (IHC).

resultsThe results indicate that in vivo administration of Apremilast is able to drive the altered profile of PsO-MSCs towards a more physiological pattern. In skin sections, the role of Apremilast is evident in reducing VEGF, iNOS and IDO expression.

conclusionApremilast treatment influences the expression of VEGF, iNOS and IDO not only by keratinocytes but also by MSCs, restoring their intrinsic profile and their natural anti-inflammatory action, and decreasing the auto-inflammatory process that underpins the development of psoriasis.

Indexed as

AdultAgedAnti-Inflammatory Agents, Non-SteroidalFemaleHumansIndoleamine-Pyrrole 2,3,-DioxygenaseMaleMesenchymal Stem CellsMiddle AgedNitric Oxide Synthase Type IIPsoriasisSkinThalidomideVascular Endothelial Growth Factor AAnti-Inflammatory Agents, Non-SteroidalapremilastIndoleamine-Pyrrole 2,3,-DioxygenaseNitric Oxide Synthase Type IINOS2 protein, humanThalidomideVascular Endothelial Growth Factor AVEGFA protein, humanApremilastIDOInflammationiNOSMSCsPsoriasisVEGF

Identifiers

PMID33210178
OpenAlexW3098559961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.